Klaria Pharma Holding AB: Klaria Year-End Report
Klaria Year-End Report 1 January-31 December 2022 Q4 2022
Summary of the Year-End Report
Successful rights issue brought 59.2 MSEK to Klaria
New collaboration agreement signed with PharmaMar fourth quarter of 2022
- Net sales amounted to 2.2 MSEK (0.0 MSEK)
- Other income amounted to 0.2 MSEK (6.2 MSEK)
- R&D costs for the period amounted to 8.6 MSEK (28.1 MSEK)
- Profit after tax amounted to -12.9 MSEK (-24.8 MSEK)
- Earnings per share for the quarter amounted to -0.22 SEK (-0.48 SEK)
- Cash flow from operating activities amounted to -10.7 MSEK (-14.6 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 16.8 MSEK (25.5 MSEK)
- Equity as of December 31 amounted to 76.0 MSEK (69.4 MSEK) The period January-December 2021
- Net sales amounted to 5.9 MSEK (0.0 MSEK)
- Other income amounted to 0,7 MSEK (37.5 MSEK)
- R&D costs for the period amounted to 51.4 MSEK (63.5 MSEK)
- Profit after tax amounted to -63.8 MSEK (-53.5 MSEK)
- Earnings per share for the quarter amounted to -1.10 SEK (-1.03 SEK)
- Cash flow from operating activities amounted to -49.8 MSEK (-24.8 MSEK)
- Cash and cash equivalents in the parent company amounted to 15.5 MSEK (9.1 MSEK)
- Equity in the parent company amounted to 175.3 MSEK (158.4 MSEK)